Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein Lin28 homolog B (LIN28B) is an evolutionarily conserved RNA-binding protein that plays a critical role in developmental timing, pluripotency, and oncogenesis. It primarily functions as a post-transcriptional repressor of the let-7 family of microRNAs by binding to their primary (pri-let-7) and precursor (pre-let-7) transcripts, thereby blocking their maturation. Because let-7 microRNAs act as key tumor suppressors that target major oncogenes such as MYC, RAS, and HMGA2, the overexpression of LIN28B leads to let-7 depletion and drives cell proliferation, metastasis, and cancer stemness. LIN28B is highly upregulated in various malignancies, including hepatocellular carcinoma, neuroblastoma, triple-negative breast cancer, and therapy-resistant prostate cancer, making it an attractive therapeutic target. Although historically considered 'undruggable' due to its lack of conventional small-molecule binding pockets, recent drug discovery efforts have identified several preclinical small-molecule inhibitors (such as Compound 1632, LI71, and ponicidin) and PROTACs that disrupt the LIN28B/let-7 interaction or induce LIN28B degradation to restore tumor-suppressive let-7 levels.
Inhibition of LIN28B binding to let-7 precursor microRNAs (pre-let-7/pri-let-7), thereby restoring let-7 maturation and suppressing downstream oncogenes (e.g., MYC, RAS, HMGA2, SOX2). Some compounds or PROTACs also induce LIN28B protein degradation.
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Lin28 homolog B (LIN28B).